How MBA was paid
$6.3M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Kevin Lee, Ph.D., MBAChief Executive Officer | $862,339 | $2,961,297 | $1,724,800 | $543,642 | $249,395 | $6,341,473 |
| Michael Skynner, Ph.D.Chief Scientific Officer | $612,471 | $836,470 | $490,000 | $319,355 | $68,714 | $2,327,010 |
| Alistair MilnesChief Corporate Development Officer | $578,189 | $836,470 | $490,000 | $322,520 | $65,245 | $2,292,424 |
What changed and why
- $6.3MCEO Kevin Lee received total compensation of $6,341,473 in 2025, an increase from $4,857,218 in 2024.
- 97%The Board determined a corporate goal achievement level of 97% for the 2025 annual bonus plan.
- Long-term equity incentives were granted through options and RSUs in January 2025.
- Corporate performance goals included clinical development progress for zelenectide pevedotin and nuzefatide pevedotin.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.